Pfizer offloaded a scrapped Seagen antibody-drug conjugate to Medicus Pharma under a transaction that could reach more than $1 billion. The move follows Pfizer’s acquisition of Seagen in a $43 billion deal and reflects portfolio pruning as the company reallocates resources across its oncology pipeline. The asset transferred is a CD228-targeted ADC, PF-08046031, described as Seagen-derived. For Medicus, the co-development rights improve access to an oncology mechanism that can potentially be advanced with updated clinical or manufacturing strategies. The deal illustrates how large pharma is continuing to recycle discontinued late-stage or deprioritized assets into smaller biotechs, while Medicus seeks to convert earlier platform investment into a new development trajectory.